Cargando…

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources. This study examined access to rituximab and identified potential barriers to its use in the United States, Mexico, Turkey, Ru...

Descripción completa

Detalles Bibliográficos
Autores principales: Baer, William H., Maini, Archana, Jacobs, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035768/
https://www.ncbi.nlm.nih.gov/pubmed/24810947
http://dx.doi.org/10.3390/ph7050530